Welcome to our dedicated page for MindWalk Holdings news (Ticker: HYFT), a resource for investors and traders seeking the latest updates and insights on MindWalk Holdings stock.
MindWalk Holdings Corp. (NASDAQ: HYFT) is a Bio-Native AI biotechnology company whose news flow centers on AI-driven biologics discovery, vaccine research and therapeutic programs. Public announcements describe a platform built on patented HYFT patterns and the LensAI software environment, combining in silico analysis with an integrated wet lab to advance drug discovery and development.
News about MindWalk often highlights progress in specific programs. The company has reported advances in a universal influenza program, stating that HYFT Deep Data technology identified a functional constraint that persists across influenza A and B viruses, including human, avian and swine-associated datasets. It has also issued updates on an AI-designed GLP-1 receptor agonist program and a proposed dual-pathway regimen that links GLP-1 biology to a second, longevity-related pathway, as well as a universal dengue vaccine initiative built around a conserved discontinuous epitope.
In neurodegeneration, MindWalk has announced the discovery and validation of monoclonal antibodies and intrabodies that selectively target misfolded, pathogenic TDP-43, a protein implicated in ALS, FTD and certain forms of Alzheimer’s disease. Additional releases cover financial results, strategic divestitures, share repurchase authorizations, at-the-market equity facilities and leadership appointments, reflecting both scientific and corporate developments.
Investors and observers using this news page can review company-issued press releases on Bio-Native AI platform advances, program milestones, capital markets activity and conference participation. The feed provides a single location to follow how MindWalk applies its HYFT and LensAI technologies across influenza, dengue, GLP-1 and neurodegenerative programs, alongside updates on its financial performance and strategic structure.
MindWalk (Nasdaq: HYFT) appointed Thomas W. Lynch, Ph.D., as Chief Business Officer effective October 20, 2025 to accelerate commercial expansion of its HYFT-powered Deep Data platform.
Dr. Lynch brings over two decades of biotech and software commercialization experience, including roles at Aldevron and DNASTAR. He led commercial teams tied to Aldevron initiatives that contributed to its $9.6B acquisition by Danaher in 2021. MindWalk said the hire supports scaling global teams and forging strategic partnerships to broaden adoption in pharma and biotech markets.
MindWalk (NASDAQ: HYFT) announced a Board‑authorized share repurchase program to buy up to 2.3 million common shares between October 15, 2025 and October 15, 2026. The authorization equals approximately 5% of the 46,154,188 shares currently outstanding. Purchases may occur on the open market or by other legally permissible means at prevailing market prices, subject to U.S. and Canadian securities rules. The company expects to fund the Program from existing cash, short‑term investments, future cash flows, or financing activities. The Program is discretionary and does not obligate any repurchases; the Board may suspend or change its terms at any time.
MindWalk Holdings (NASDAQ:HYFT) has announced a significant advancement in its AI-designed GLP-1 therapeutics program, unveiling a novel dual-pathway regimen for aging and longevity applications. The company's LensAI™ platform has identified a previously unknown connection between GLP-1 biology and a second pathway crucial for healthy aging.
The breakthrough involves a first-in-class treatment approach combining MindWalk's proprietary companion therapeutic with its GLP-1 receptor agonists (GLP-1RAs). This development targets the longevity therapeutics market, projected to reach $60 billion by 2030. Earlier this year, the company's AI-designed GLP-1 peptides demonstrated performance matching or exceeding semaglutide in receptor activation assays.
MindWalk Holdings Corp. (NASDAQ: HYFT), formerly ImmunoPrecise Antibodies, reported strong financial results for Q1 FY2026. The Bio-Native AI company achieved record revenue of $7.6 million, representing a 45% year-over-year growth, with continuing operations contributing $3.2 million.
Key financial metrics showed significant improvement with gross margin expanding to 53% and net loss narrowing to $3.0 million from $4.0 million last year. The company's cash position stands at $5.0 million, supplemented by $16.1 million in net proceeds from the Netherlands operations divestiture.
Strategic developments include the company's rebranding to MindWalk, advancement of their dengue vaccine program into preclinical manufacturing, and expanded validation of their LensAI platform for biologics development risk assessment.
MindWalk (NASDAQ: HYFT), a bio-native AI company focused on TechBio and drug discovery, will release its Q1 FY2026 financial results on September 15, 2025. The company will host a conference call and webcast at 10:30 AM ET to discuss quarterly results and business highlights.
The earnings call will include a management presentation followed by a Q&A session. Participants can join via phone using various dial-in numbers (US/International: +1-646-307-1963, Toll-free: 800-715-9871) with Conference ID 3224490, or through the webcast link available on the company's IR website.